NBIX compared with INCY: revenue, margins and what each company keeps, and the suppliers and customers both name

NBIXNeurocrine Biosciences Inc

Mkt capRevenueRevenue

INCYIncyte Corp

Mkt capRevenueRevenue

Compare

NBIXNeurocrine Biosciences Inc

INCYIncyte Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NBIX

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.3%▲+13.42%×1.44

Q2 FY26—▼−10.08%—

Q1 FY26—▲+8.86%—

Feb 12 '26—▼−10.43%—

INCY

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.5%▼−0.06%×0.01

Q2 FY26±7.4%▲+9.30%×1.26

= impliedNBIX realized, solidINCY realized, hatchedOne scale, both sides: full bar = 14%× = |realized| ÷ impliedSource: market data

Q1 FY26

±6.9%

▲+2.12%

×0.30

Feb 10 '26±6.2%▼−8.24%×1.32

NBIXNeurocrine Biosciences Inc

168.91▲+2.60%· post 169.44· delayed

Mkt cap$16.7BRevenue$1.1BQ3 FY26Revenue$2.9BFY25

INCYIncyte Corp

121.88▲+1.86%· post 121.41· delayed

After hoursNov 9 '26delayed

Mkt cap$24.4BRevenue$1.6BQ3 FY26Revenue$5.1BFY25

Compare

After hoursNov 9 '26delayed

NBIXNeurocrine Biosciences Inc

INCYIncyte Corp

168.91▲+2.60%post 169.44delayed

Price

121.88▲+1.86%post 121.41delayed

$16.7B

Mkt cap

$24.4B

Q3 FY26$1.1B

Revenue

$1.6BQ3 FY26

FY25$2.9B

Revenue

$5.1BFY25

NBIX168.91▲+2.60%vsINCY121.88▲+1.86%After hoursNov 9 '26delayed